^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    EZH2 mutation + BCL2 translocation

    i
    Other names: EZH2, ENX-1, EZH1, KMT6, KMT6A, Enhancer of zeste 2 polycomb repressive complex 2 subunit, BCL2, Bcl-2, PPP1R50, B-cell CLL/lymphoma 2
    Entrez ID:
    596; 2146
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    over1year
    Expression Signature and Prognostic Value of BCL2 Translocation for Diffuse Large B-Cell Lymphoma Patients in China (ASH 2022)
    The presence of CCND3 mutations tended to have negative prognostic effects on PFS (HR: 31.8, 95%CI: 2.7-371.5, P = 0.004) and OS (HR:18.6, 95%CI:2.6-133.9, P = 0.006), in patients with BCL2 translocations.Conclusion :In DLBCL patients harboring both BCL2 and MYC translocation are most likely resulting in aggressive clinical behavior, while BCL2 translocation alone has similar prognosis with DLBCL patients without BCL2 rearrangement. DLBCL patients contained BCL2 translocation (with or without MYC rearrangement) demonstrate a higher proportion of mutation associated with epigenetic modify, which may benefited from epigenetic therapy.
    Clinical • IO biomarker
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6) • KMT2D (Lysine Methyltransferase 2D) • CREBBP (CREB binding protein) • EP300 (E1A binding protein p300) • TNFRSF14 (TNF Receptor Superfamily Member 14) • CCND3 (Cyclin D3) • STAT6 (Signal transducer and activator of transcription 6) • TNFRSF18 (TNF Receptor Superfamily Member 18)
    |
    MYC rearrangement + BCL2 rearrangement • EZH2 mutation • MYC rearrangement • MYC translocation • BCL2 rearrangement • EZH2 mutation + BCL2 translocation • BCL2 translocation
    over3years
    Combined EZH2 and Bcl-2 inhibitors as precision therapy for genetically defined DLBCL subtypes. (PubMed, Blood Adv)
    The combination of tazemetostat and venetoclax was also synergistic in vivo. In DLBCL PDXs, short-course combination therapy resulted in complete remissions that were durable over time and associated with superior overall survival compared with either drug alone.
    Journal
    |
    EZH2 (Enhancer of zeste 2 polycomb repressive complex 2 subunit)
    |
    EZH2 mutation • EZH2 mutation + BCL2 translocation
    |
    Venclexta (venetoclax) • Tazverik (tazemetostat)